HD5
HD5 is an innate immune effector peptide and SARS-CoV Inhibitor. HD5 binds to the ligand-binding domain of angiotensin-converting enzyme-2 (ACE2) via multiple hydrogen bonds to competitively block the receptor, shielding it from viral recognition. HD5 can be used for the research of COVID-19, HPV16 infection, epithelial ovarian cancer, small-cell lung cancer, and colon cancer.
For research use only. We do not sell to patients.
- CAS No.: 798569-33-2
- Formula: C144H238N50O45S6
- Molecular Weight:3582.14
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
HD5 binds with high affinity to the ligand-binding domain of host cell ACE2, competitively blocking and shielding the receptor to prevent SARS-CoV-2 recognition and infection of host cells[1].
HD5 (20 µM) binds to regions of HPV16 L1 and L2 capsid proteins[2].
HD5 (15 μM; 5 days) significantly inhibits the spread and cytolytic activity of PtDd-deficient mut-Ad3GFP in A549 cells, while only minimally impacting PtDd-producing wt-Ad3GFP[3].
HD5 (0.1 μM) binds to HAdV3 penton base, fiber, fiber knob, and multimeric penton base-containing structures (PtDd and virion-associated penton bases) in a Western blot assay[3].
HD5 significantly inhibits progeny virus production and spread of PtDd-deficient mut-Ad3GFP in Caco-2 and T84 cells, while PtDd-producing wt-Ad3GFP is unaffected[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 798569-33-2
-
Molecular Weight 3582.14
-
Formula C144H238N50O45S6
-
Sequence
Ala-Thr-Cys-Tyr-Cys-Arg-Thr-Gly-Arg-Cys-Ala-Thr-Arg-Glu-Ser-Leu-Ser-Gly-Val-Cys-Glu-Ile-Ser-Gly-Arg-Leu-Tyr-Arg-Leu-Cys-Cys-Arg (disulfide bridge:Cys3-Cys31,Cys5-Cys20,Cys10-Cys30)
-
Sequence Shortening
ATCYCRTGRCATRESLSGVCEISGRLYRLCCR (disulfide bridge:Cys3-Cys31,Cys5-Cys20,Cys10-Cys30)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
[1]. Mahendran ASK, et al. The Potential of Antiviral Peptides as COVID-19 Therapeutics. Front Pharmacol. 2020 Sep 15;11:575444. [Content Brief]
[2]. Gulati NM, et al. α-Defensin HD5 Stabilizes Human Papillomavirus 16 Capsid/Core Interactions. Pathog Immun. 2019 Sep 12;4(2):196-234. [Content Brief]
[3]. Vragniau C, et al. Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy. J Virol. 2017;91(6):e02030-16. Published 2017 Feb 28. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)